Every two weeks, 40 mg of standard biosimilar adalimumab (Bs-ADA, ExemptiaTM) was administered subcutaneously for six injections (10 weeks) or to continue with standard follow-up if they did not achieve an Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) index response by week 12. The gene discussed is ADA; the disease is spondylitis.